AI Article Synopsis
- The study assessed the impact of 3D conformal thoracic radiotherapy (TRT) combined with chemotherapy on patients with extensive-stage small-cell lung cancer (ES-SCLC).
- A total of 165 patients were analyzed, showing improved overall survival (OS) and progression-free survival (PFS) rates in the group receiving chemotherapy alongside TRT compared to those receiving chemotherapy alone.
- Key findings include a median OS of 15 months and a favorable prognosis associated with receiving at least 4 cycles of chemotherapy and TRT, indicating that TRT enhances treatment outcomes for ES-SCLC patients.
Article Abstract
The aim of the present study was to evaluate the effect of 3-dimensional conformal thoracic radiotherapy (TRT) on extensive-stage small-cell lung cancer (ES-SCLC). A total of 165 patients with ES-SCLC were enrolled in the present study, including 82 patients receiving chemotherapy combined with TRT (the ChT/TRT group) and 83 patients receiving chemotherapy alone (the ChT group). The overall survival (OS) and progression-free survival (PFS) rates were compared between the ChT/TRT and ChT groups, and the prognostic factors for OS rate were identified. It was found that the patients had a median OS time of 15 months, and 2- and 5-year OS rates of 31.5 and 2.4%, respectively. The 2- and 5-year OS rates were 35.3 and 2.4% in the ChT/TRT group, and 14.5 and 2.4% in the ChT group, respectively (P<0.05). The 1- and 2-year PFS rates were 35.4 and 6.0% in the ChT/TRT group, and 20.5 and 6.0% in the ChT group, respectively (P<0.05). The median PFS was 11 months in the 20 patients receiving TRT at 45 Gy/30 fractions twice daily, and 9 months in the 22 patients receiving TRT at 60 Gy/30 fractions daily (P=0.043). Multivariate analysis revealed that receiving ≥4 cycles of chemotherapy (P=0.001) and TRT (P=0.008) were favorable prognostic factors for OS. It was concluded that the addition of TRT improves the OS and PFS rates of patients with ES-SCLC, and TRT administration at 45 Gy/30 fractions twice daily is feasible and tolerable for the treatment of ES-SCLC. Thus, TRT and receiving ≥4 cycles of chemotherapy are independent, favorable prognostic factors for OS in patients with ES-SCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509057 | PMC |
| http://dx.doi.org/10.3892/etm.2015.2526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guanidyl-rich α-helical polypeptide enables efficient cytosolic pro-protein delivery and CRISPR-Cas9 genome editing.
J Mater Chem B
January 2025
Department of Thoracic Cancer, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Intracellular delivery of proteins has attracted significant interest in biological research and cancer treatment, yet it continues to face challenges due to the lack of effective delivery approaches. Herein, we developed an efficient strategy cationic α-helical polypeptide-mediated anionic proprotein delivery. The protein was reversibly modified with adenosine triphosphate dynamic covalent chemistry to prepare an anionic proprotein (A-protein) with abundant phosphate groups.
View Article and Find Full Text PDFRelationship between gender and perioperative clinical features in lung cancer patients who underwent VATS lobectomy.
J Cardiothorac Surg
December 2024
Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, P.R. China.
Objectives: Compare the differences in perioperative clinical characteristics of lung cancer patients of different genders who have undergone VATS lobectomy, and explore the impact of these differences on the short-term prognosis of patients.
Methods: A total of 338 consecutive patients with lung cancer who underwent VATS lobectomy in our hospital from August 2021 to August 2022 were retrospectively analyzed, they were divided into male group and female group. The perioperative characteristics and short-term prognosis of different groups were compared.
Microcardia and cardiomegaly screening using postero-anterior chest X-ray (PA CXR) across university students in Ghana - a retrospective study.
BMC Med Imaging
December 2024
Department of Radiology, School of Medicine, University of Health and Allied Sciences (UHAS), Ho, Ghana.
Background: Microcardia and cardiomegaly are good diagnostic and prognostic tools for several diseases. This study investigated the distribution of microcardia and cardiomegaly among students of the University of Health and Allied Sciences (UHAS) in Ghana to determine the prevalence of microcardia and cardiomegaly across gender, and to evaluate the correlation between the presence of these heart conditions and age.
Methods: This retrospective study involved a review of 4519 postero-anterior (PA) chest X-rays (CXRs) between 2020 and 2023.
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial.
EClinicalMedicine
January 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Background: The absolute overall survival (OS) improvement with preoperative chemotherapy or chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) patients is controversial and unsatisfactory. We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy.
Methods: Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China.
A multicenter clinical trial on the five-year outcomes following treatment of acute, complicated type B aortic dissection with a conformable stent graft.
Ann Vasc Surg
December 2024
Division of Vascular and Endovascular surgery, St. Elizabeth's Medical Center, Boston, Massachusetts.
Objective: Thoracic endovascular repair (TEVAR) has become the treatment of choice for acute, complicated type B aortic dissections. The purpose of this study was to evaluate the 5-year outcomes of the GORE TAG 08-01 study on TEVAR for acute, complicated type B aortic dissections using the Conformable GORE® TAG® Thoracic Endoprosthesis (CTAG), and to establish if late aortic complications are avoided and remodeling is sustained.
Methods: From January 2010 to February 2017, 50 patients with acute, complicated type B aortic dissections were enrolled from 26 sites in the U.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!